pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
DUPIXENT · news · pharmadog
← back to DUPIXENT
News mentioning DUPIXENT
44
stories
4d
Lilly, Foghorn part ways; Wave’s FDA-approved plans
biopharma dive
4d
Sanofi, Regeneron broaden alliance to find their next Dupixent
biopharma dive
4d
Pfizer’s eczema drug clears skin in mid-stage trial
biopharma dive
4d
Sanofi pays Regeneron $1B upfront to continue search for Dupixent successor
biospace
4d
Sanofi builds on immunology alliance with Regeneron for $1B upfront
endpoints
4d
STAT+: Sanofi, Regeneron expand partnership after Dupixent success
stat
4d
Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D
fiercebiotech
4d
Recon: Sanofi, Regeneron expand partnership after Dupixent success; Lilly amylin-Zepbound combo succeeds in mid-stage trial
raps
5d
Connect’s Dupixent rival reduces COPD attacks by 85%, but misses a secondary goal
fiercebiotech
7d
6 immunology targets to sustain a mammoth I&I market
biospace
12d
Enveda, an AI drugmaker, banks $311M in venture funding
biopharma dive
13d
Celldex sinks as safety concerns cloud immune drug results
biopharma dive
18d
North Immunology joins biotech reverse merger boom with Aethlon deal
biopharma dive
18d
North Immunology goes public via reverse merger as eczema drug heads toward clinic
fiercebiotech
20d
Connect's Dupixent rival flunks phase 2 asthma trial, but biotech sees reasons for hope
fiercebiotech
24d
Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
biopharma dive
27d
AZ's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPD
fiercebiotech
Aug 28, 26
AstraZeneca, Amgen poised to challenge Dupixent’s reign with esophagitis win
biospace
Aug 27, 26
New data could widen use of AstraZeneca, Amgen immune disease drug
biopharma dive
Aug 25, 26
Founded by Metsera backers, Sentivera emerges with $1.5B inflammatory disease deal
fiercebiotech
Aug 18, 26
Regeneron ends eye disease study due to antibody's safety profile
biospace
Aug 18, 26
Regeneron ends eye disease study due to antibody's safety profile
biospace
Aug 11, 26
Chasing Dupixent, a biotech aims to make better antibody drugs for eczema
biopharma dive
Aug 10, 26
Regeneron backs $75M series A for antibody upstart Infinimmune
fiercebiotech
Aug 6, 26
Braveheart pumps more life into biotech IPO market with $382M expected debut
biospace
Aug 6, 26
Sanofi pauses mid-stage lung study amid new CEO’s ‘rigorous portfolio prioritization’
biospace
Aug 5, 26
A COPD drug from China draws $115M in venture funding
biopharma dive
Aug 5, 26
Attovia's CEO aims to scratch itch opportunity and challenge Dupixent with $289M IPO
fiercebiotech
Jul 31, 26
AbbVie shares pressured as Q2 I&I beat falls below investor expectations
biospace
Jul 31, 26
Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs
biopharma dive
← prev
page 1 of 2
next →
